- CLINICAL PROTOCOL AND DATA MANAGEMENT Part I: Clinical Protocol and Data Management (CPDM). CPDM facilitates all clinical cancer research at The Ohio State University Comprehensive Cancer Center (OSUCCC) and is responsible for 14,996 interventional (5,648 interventional therapeutic) accruals over the reporting period. The CPDM has three major components: the Clinical Trials Office (CTO), the Quality Assurance (QA) Office and the OSUCCC Data and Safety Monitoring Plan (DSMP). Oversight is provided by the Associate Director for Clinical Research (ADCR), William Carson, MD, who also is serving as the interim CTO Medical Director. Dr. Carson supervises the CTO Administrative Director, Angela Campbell, MS, assisted by the Executive Director for Administration, David Gosky, MA, MBA. The CTO provides investigators with centralized expertise and support for the implementation, coordination and execution of cancer clinical trials. The CTO staff focuses on OSUCCC?s mission, vision and values to support investigators in the highest quality clinical cancer research with adherence to all federal and state guidelines. Part II: Data and Safety Monitoring. All cancer clinical trials conducted by OSUCCC investigators include oversight of data and safety monitoring. The OSUCCC Data and Safety Monitoring Plan (DSMP), approved by the NCI and last revised August 1, 2018, provides guidance for the conduct of cancer clinical trials in accordance with NCI CCSG requirements. The Data and Safety Monitoring Committee (DSMC), chaired by Beth Christian, MD, assures patient safety and protocol compliance by OSUCCC investigators and staff, and has monitored 413 trials during the reporting period. The independent control function for OSUCCC studies is provided by the Quality Assurance Oversight Committee (QAOC), which has audited 180 trials over the reporting period. Part III: Inclusion of Women and Minorities in Clinical Research. OSUCCC leadership, investigators and staff are committed to the inclusion of women and minorities in cancer clinical trials. Oversight of the inclusion of diverse populations in cancer clinical trials is the responsibility of Dr. Carson, who is assisted by Electra Paskett, PhD, Associate Director for Population Sciences and Community Outreach and Director of the Center for Cancer Health Equity (CCHE). Outreach to women and minorities is led by CCHE staff who educate the community about OSUCCC programs, services and the value of clinical trials. Part IV: Inclusion of Individuals Across the Lifespan in Clinical Research. The inclusion of individuals across the lifespan in cancer clinical research is an important goal of the OSUCCC. Nationwide Children?s Hospital (NCH) is the pediatric arm of the OSUCCC and is committed to making clinical trials available to children with a cancer diagnosis. It is the policy of the OSUCCC that individuals of all ages, including children and older adults are included in cancer clinical trials. In summary, the OSUCCC facilitates clinical cancer research, and provides quality, safety and monitoring of all trials with an emphasis on the inclusion of women, minorities, other underserved populations and individuals across the lifespan in its catchment area (the State of Ohio).

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Pan, Pan; Oshima, Kiyoko; Huang, Yi-Wen et al. (2018) Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. Int J Cancer 143:886-896

Showing the most recent 10 out of 2602 publications